Dr. Morris and future Distinguished Scholars will create and manage an original educational project to disseminate new knowledge about thrombosis and advance the creation of best practices in patient care. Specifically, Dr. Morris will explore pulmonary care in his project "Learning From Ourselves: Application of the Continuous Quality Improvement Model for Management of Pulmonary Embolism." He will receive an annual stipend over a three-year period and then serve as a mentor for the next Distinguished Scholar.
"The Distinguished Scholar presents an opportunity to make an outstanding contribution to the diagnosis and treatment of thrombosis," said Diane E. Stover, MD, FCCP, President of The CHEST Foundation. "By taking a unique approach, the scholar can explore and promote alternatives for the treatment of thrombosis that will ultimately benefit many patients."
Traditionally, funding is available for scholars to do clinical research or basic science. The Distinguished Scholar award will instead support activities such as the development of public policy, patient education models, or economic analysis of treatment or care delivery in this patient group. Organon Sanofi~Synthelabo's investment in the Distinguished Scholar program reflects the importance of promoting new knowledge about thrombosis that will translate into improvement in clinical practice and saving lives.
"The Distinguished Scholar program makes it possible for a talented specialist to develop groundbreaking work that can bring a new approach to treating people with pulmonary embolism," said Warren Czerniak, general manager, Organon Sanofi-Synthelabo LLC. "Our company is proud to make this investment in such a worthwhile effort."
CHEST is the 69th annual international scientific assembly of the American College of Chest Physicians, being held in Orlando, October 25-30. ACCP represents 15,700 members who provide clinical respiratory, critical care, and cardiothoracic patient care in the United States and throughout the world. ACCP's mission is to promote the prevention and treatment of diseases of the chest through leadership, education, research, and communication. The CHEST Foundation is the philanthropic arm of the College whose mission is to improve lung health for patients and communities through education focused on public health issues.
Organon Sanofi-Synthelabo is a limited liability company, the members of which are Organon Pharmaceuticals USA Inc. and Sanofi-Synthelabo Inc.
Organon Pharmaceuticals USA Inc. - headquartered in Roseland, NJ - creates and markets prescription medicines that improve the health and quality of human life. Organon strives to be one of the top global pharmaceutical companies in each of its core therapeutic fields: gynecology, central nervous system, cardiovascular disease and anesthesiology. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. For more information, visit www.organonusa.com.
Sanofi-Synthelabo is a major global research-based pharmaceutical group with 32,500 employees in more than 100 countries. The company is headquartered in Paris and listed in Paris (Euronext : SAN) and in New York (NYSE : SNY). With consolidated sales of EUR 7.4 billion in 2002, Sanofi-Synthelabo ranks 7th in Europe and among the world's top 20 pharmaceutical companies. With an R&D portfolio of 52 compounds in development, Sanofi-Synthelabo is focused on a core group of four therapeutic areas: cardiovascular disease and thrombosis; diseases of the central nervous system; internal medicine; and oncology.
For more information about the Distinguished Scholar program, visit www.chestnet.org.